Search research articles
Contact Us
Filters
Showing results (411-420 of 499) with videos related to
Page
of 50
Sort By:
Cancer Discovery
|
May 13, 2015
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Rodrigo Dienstmann, Amita Patnaik, Rocio Garcia-Carbonero, et al.
The Lancet. Oncology
|
November 18, 2021
<sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Jonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
The Oncologist
|
September 8, 2018
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Potential regional differences for the tolerability profiles of fluoropyrimidines
Daniel G Haller, Jim Cassidy, Stephen J Clarke, et al.
The New England Journal of Medicine
|
September 16, 2024
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
Kohei Shitara, Manish A Shah, Florian Lordick, et al.
Future Oncology (London, England)
|
February 12, 2025
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
Lancet (London, England)
|
September 14, 2023
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
Journal of the National Cancer Institute
|
March 18, 2021
BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database
Romain Cohen, Heshan Liu, Jack Fiskum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
Journal of the National Cancer Institute
|
September 10, 2021
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials
Jun Yin, Mohamed E Salem, Jesse G Dixon, et al.
Page
of 50
Search research articles
Search
Showing results (411-420 of 499) with videos related to
Sort By:
Page
of 50
Cancer Discovery
|
May 13, 2015
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Rodrigo Dienstmann, Amita Patnaik, Rocio Garcia-Carbonero, et al.
The Lancet. Oncology
|
November 18, 2021
<sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Jonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
The Oncologist
|
September 8, 2018
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem, Erika Martinelli, Stefano Cascinu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2008
Potential regional differences for the tolerability profiles of fluoropyrimidines
Daniel G Haller, Jim Cassidy, Stephen J Clarke, et al.
The New England Journal of Medicine
|
September 16, 2024
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
Kohei Shitara, Manish A Shah, Florian Lordick, et al.
Future Oncology (London, England)
|
February 12, 2025
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
Lancet (London, England)
|
September 14, 2023
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
Journal of the National Cancer Institute
|
March 18, 2021
BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database
Romain Cohen, Heshan Liu, Jack Fiskum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
Journal of the National Cancer Institute
|
September 10, 2021
Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials
Jun Yin, Mohamed E Salem, Jesse G Dixon, et al.
Page
of 50